Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Florence Joly1, Isabelle Ray-Coquard2

  • 1Département d'oncologie médicale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France; Intergroupe GINECO, Paris France.

Bulletin Du Cancer
|December 27, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same authorSame journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same author

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Updated guidelines for high-grade ovarian cancer incorporate PARP inhibitors and molecular profiling. These advancements improve treatment strategies and patient outcomes, especially for BRCA-mutated cases.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Molecular Oncology

Background:

  • Ovarian cancer management has evolved significantly since 2013/2016 recommendations.
  • Increased complexity due to surgical quality criteria and molecular biology integration.
  • High-grade epithelial ovarian cancers require precise, updated treatment strategies.

Purpose of the Study:

  • To update clinical practice guidelines for high-grade ovarian epithelial cancer.
  • Disseminate recent advances in surgical and medical management.
  • Improve daily practice for oncologists treating ovarian cancer.

Main Methods:

  • Review and integration of recent clinical practice recommendations.
  • Focus on surgical indications in first-line and relapse settings.
Keywords:
Analyse moléculaireCancer épithélialGuidelinesHigh grade epithelialInitial treatmentMedical treatmentMolecular analysisPrise en charge initialeRéférentielsStratégie chirurgicaleSurgical strategyTraitements médicauxde haut gradede l’ovaireovarian cancer

Related Experiment Videos

  • Incorporation of molecular profiling, including BRCA status and HRD testing.

    • Main Results:

    • PARP inhibitors demonstrate significant efficacy in maintenance therapy post-chemotherapy.
    • PARP inhibitors show benefit in first-line treatment, improving progression-free survival.
    • Molecular profiling (BRCA, HRD) guides the use of PARP inhibitors and bevacizumab.

    Conclusions:

    • Current strategies integrate PARP inhibitors and bevacizumab based on platinum response and molecular profile.
    • Early testing for BRCA and HRD abnormalities is crucial for treatment decisions.
    • Updated guidelines aim to enhance ovarian cancer patient care through advanced therapies.